Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).
China Resources Pharmaceutical Group Ltd. has called its annual general meeting for 12 June 2026 in Hong Kong to review the audited financial statements for the year ended 31 December 2025 and to seek shareholder approval for key corporate matters. The board is proposing a final dividend of RMB0.122 per share, the re-election of several executive, non-executive and independent non-executive directors, and authorization for the board to set directors’ and auditor KPMG’s remuneration.
Shareholders will also be asked to approve a general mandate allowing the board to repurchase up to 10% of the company’s issued shares on the Hong Kong Stock Exchange or other recognized exchanges, subject to regulatory limits and adjustments for any share consolidation or subdivision. The combination of dividend declaration, director re-elections and the potential buy-back mandate underscores the company’s focus on capital management, governance continuity and shareholder returns ahead of its next financial reporting cycle.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a Hong Kong-incorporated pharmaceutical company focused on the manufacture, distribution and sale of medicines and healthcare products in mainland China and other markets. The group operates across the pharmaceutical value chain, supported by its listing on the Hong Kong Stock Exchange, and targets both institutional and retail healthcare customers.
YTD Price Performance: 10.79%
Average Trading Volume: 20,168,986
Technical Sentiment Signal: Sell
Current Market Cap: HK$30.97B
For detailed information about 3320 stock, go to TipRanks’ Stock Analysis page.